Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page
- Check7 days agoChange DetectedVersion 5 (2023-03-07) was added to the history, updating Recruitment Status, Study Status, and Study Design. This revision reflects the trial's current activity and design details.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check35 days agoChange Detected- Updated the page to v3.2.0 and added a government-operational status notice clarifying potential delays and open status of NIH Clinical Center. - Removed the previous version tag v3.1.0.SummaryDifference12%

- Check43 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No other substantive content changes are indicated.SummaryDifference0.3%

- Check57 days agoChange DetectedThe page version updated from v3.0.1 to v3.0.2, signaling a minor content update; the 'Back to Top' link was removed, a minor UI change.SummaryDifference0.7%

- Check64 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.SummaryDifference0.7%

- Check71 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, while several location-related details have been removed.SummaryDifference8%

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.